Cite

HARVARD Citation

    Láinez, M. et al. (2022). Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment. Headache. 62 (1), pp. 65-77. [Online]. 
  
Back to record